Why Disc Medicine’s latest trial milestones matter for investors

Disc Medicine (IRON) has moved its pipeline forward by completing enrollment in the pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria, while also preparing new data readouts across other hematology programs.

The latest trial milestones arrive after a mixed stretch in the market, with the share price at US$67.53 showing a 1-year total shareholder return of 52.47% alongside a 14.62% year to date share price decline and 108.23% total shareholder return over three years. This suggests long term momentum even as shorter term sentiment has cooled around recent losses and higher spending.

If pipeline news has you thinking about what else is moving in healthcare, this is a good moment to widen your search with 35 healthcare AI stocks

With the stock at US$67.53, a 47% implied discount to one intrinsic value estimate and a similar gap to the average analyst target raises the key question: is Disc Medicine still undervalued, or is the market already pricing in future growth?

Price-to-book of 3.7x: Is it justified?

Disc Medicine trades at a P/B of 3.7x, which sits above the broader US biotechs industry average of 2.5x, even as the stock is loss making and still pre revenue.

P/B compares the company’s market value to its net assets. For a clinical stage biopharmaceutical business with $0 revenue and a net loss of $241.603m, this ratio is largely about what investors are willing to pay for the pipeline, intellectual property and future potential rather than current earnings power.

Relative to peers, the current 3.7x P/B suggests investors are paying a richer price tag than the industry average 2.5x. However, it is described as good value versus a peer group average of 4x, which indicates the market is marking Disc Medicine at a slight discount to closer comparables despite its unprofitable status and very limited current revenue base.

Result: Price-to-book ratio of 3.7x (ABOUT RIGHT)

However, investors still face clear risks, including the company’s US$241.603m net loss and the possibility that key clinical trials or regulatory timelines may disappoint expectations.

Another way to look at value: cash flows vs book value

The P/B of 3.7x points to a stock that screens as expensive against the broader US biotechs industry, yet still cheaper than closer peers. Our DCF model tells a different story, with an estimated fair value of $127.95 that frames the current $67.53 price as trading at a steep discount. If the market is right about the P/B signal, what is the DCF missing? And if the DCF is closer to reality, how patient do you need to be?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Disc Medicine for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals across valuation and clinical progress, the sentiment here is cautious optimism. Consider acting promptly, reviewing the data, and weighing both 2 key rewards and 3 important warning signs

Ready for more investment ideas?

If you stop at one stock, you could miss opportunities that better fit your goals, so broaden your watchlist with a few focused screens built for different styles.

• Target value driven opportunities by checking companies that currently appear mispriced on fundamentals with the 51 high quality undervalued stocks
• Strengthen your capital preservation focus by reviewing companies with resilient profiles using the 72 resilient stocks with low risk scores
• Get ahead of the market by scanning a screener containing 23 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.